Related sites
الخط الساخن للخدمات الصحية للنازحين اللبنانيين 1787   
الخط الساخن لدخول المرضى الى المستشفيات 01/832700   
التسجيل لأخذ لقاح الكورونا covax.moph.gov.lb   
الخط الساخن لوزارة الصحّة العامة 1214   
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

الصحة النفسية: دعوة للشراكة مع المؤسسات العامة والأكاديميا ومنظمات المجتمع المدني


The Ministry of Public Health’s Vision is that of “An equitable health system that identifies and addresses the key determinants of physical and mental health and promotes, develops and sustains the highest attainable physical and mental health status of all Lebanese.”
 
To achieve this vision, the Ministry aims at building and sustaining an effective, high impact organization and works in partnership with all stakeholders, following good governance principles, to develop its institutional capacity for effective stewardship of the health sector, to ensure the promotion of better health and the provision of equitable, efficient and quality health services, in both public and private sector, that respond to people’s needs, with particular emphasis on the disadvantaged and vulnerable populations, thereby contributing to sustainable development of the country.
 
The Ministry thereby adopts an open-network collaborative type of governance for the health system based on an inter-sectoral approach and cooperates with other ministries, the private sector and the Civil Society in order to achieve its goals. As emphasized by the Director-General of Health, Professor Walid Ammar, during his address as the Laureat of the renewed Shousha Foundation Prize by the WHO for his significant contribution to public health in Lebanon:

“If I should attribute progress to one single characteristic of the health system, I would say: innovative governance. The most difficult leadership is that of getting things done by a multitude of stakeholders with different agenda, interests, and beliefs. The Lebanese society is plural and diverse by its different confessions and political groups, a strong private-for-profit sector and an active civil society with powerful NGOs. Considering the very limited resources and weak authority of the public sector, the challenge is how to make all these partners work together to achieve national health goals. The answer is to find a non-hierarchical governance structure, that replaces control and command leadership, by a collaborative leadership to achieve common goals through an open networking type of governance”. 

The MOPH promotes partnership with not only governmental entities but also non-governmental entities to achieve national goals through innovative governance mechanisms, such as inter-ministerial collaboration to promote inter-sectoral action, public-private partnership to jointly address national system challenges such a fragmentation of health financing and service provision, partnerships with  academia, including University Hospitals, to strengthen health systems and implementation research in order to further improve health services and ensure alignment of efforts towards achieving national health goals.
    1
ATC Name B/G Ingredients Dosage Form ↑ Price
J01DD15 XEVANEER G Cefdinir - 300mg 300mg Capsule 1,350,562 L.L
L01ED01 XALKORI B Crizotinib - 250mg 250mg Capsule L.L
A08AB01 XENICAL B Orlistat - 120mg 120mg Capsule 4,036,903 L.L
L01ED01 XALKORI B Crizotinib - 250mg 250mg Capsule 347,644,061 L.L
L01ED01 XALKORI B Crizotinib - 200mg 200mg Capsule 347,644,061 L.L
L02BB04 XTANDI B Enzalutamide - 40mg 40mg Capsule, soft 278,248,572 L.L
D07AC13 XEMADERM G Mometasone furoate - 0.1% 0.1% Cream 335,961 L.L
S01ED51 XOLAMOL G Timolol (maleate) - 5mg/ml, Dorzolamide HCl - 20mg/ml Drops solution 678,640 L.L
S01ED51 XALACOM B Timolol (maleate) - 6.8mg/ml, Latanoprost - 50?g/ml Drops solution 510,660 L.L
S01EE01 XALATAN B Latanoprost - 50mcg/ml 50mcg/ml Drops solution 704,173 L.L
S01EE01 XALAPROST G Latanoprost - 0.005% w/v 0.005% w/v Drops solution 421,967 L.L
B02BD02 XYNTHA BioTech Moroctocog alfa - 500IU 500IU Injectable lyophilised powder for solution+diluent L.L
B02BD02 XYNTHA BioTech Moroctocog alfa - 500IU 500IU Injectable lyophilised powder for solution+diluent 23,067,288 L.L
B02BD02 XYNTHA BioTech Moroctocog alfa - 500IU 500IU Injectable lyophilised powder for solution+diluent L.L
M03AX01 XEOMIN BioTech Clostridium botulinum type A neurotoxin complex - 100 units LD50 100 units LD50 Injectable powder for solution 20,517,541 L.L
M03AX01 XEOMIN BioTech Clostridium botulinum type A neurotoxin complex - 50 units LD50 50 units LD50 Injectable powder for solution 11,920,109 L.L
R03DX05 XOLAIR BioTech Omalizumab - 150mg 150mg Injectable solution L.L
R03DX05 XOLAIR BioTech Omalizumab - 150mg 150mg Injectable solution 30,766,872 L.L
M05BX04 XGEVA BioTech Denosumab - 120mg 120mg Injectable solution 33,545,669 L.L
A10AE56 XULTOPHY BioTech Insulin degludec - 100U/ml, Liraglutide - 3.6mg/ml Injectable solution 13,503,847 L.L
A10AE56 XULTOPHY BioTech Insulin degludec - 100U/ml, Liraglutide - 3.6mg/ml Injectable solution 13,503,847 L.L
J01DD15 XEVANEER G Cefdinir - 125mg/5ml 125mg/5ml Powder for suspension 1,308,903 L.L
J01DD15 XEVANEER G Cefdinir - 125mg/5ml 125mg/5ml Powder for suspension 686,704 L.L
R01AA07 XYLO-COMOD G Xylometazoline HCl - 0.1% 0.1% Solution 498,566 L.L
H02AB06 XILONE FORTE G Prednisolone sodium phosphate - 15mg/5ml 15mg/5ml Solution 235,172 L.L
D04AB01 XYLOCAINE B Lidocaine - 10mg/spray dose 100mg/ml Spray 667,890 L.L
A10BD15 XIGDUO XR B Metformin HCl XR - 1000mg, Dapagliflozin - 10mg Tablet 3,006,579 L.L
L04AA29 XELJANZ B Tofacitinib - 5mg 5mg Tablet L.L
N05AX12 XALIPRO G Aripiprazole - 10mg 10mg Tablet 2,123,271 L.L
N05AX12 XALIPRO G Aripiprazole - 15mg 15mg Tablet 2,418,917 L.L
    1
Sitemap
© Copyrights reserved to Ministry of Public Health 2026